CD274 and non-small cell lung carcinoma: In addition, the administration of carboplatin, cisplatin, and gemcitabine increases the PD-L1 expression on tumor cells, and shows a better efficacy when combining with ICIs in NSCLC mouse models (53–55), in which the role of cisplatin has been validated in human NSCLC tumor samples (56).